文献速递肝病消化道肿瘤与早癌消化内镜

低剂量贝伐珠单抗联合阿替利珠单抗通过纠正血管免疫微环境功能障碍增强肝细胞癌TACE疗效

Low-dose bevacizumab plus atezolizumab enhances transarterial chemoembolization in HCC via correcting vascular-immune niche dysfunction.
PubMed 文献 · J Hepatol · 2026-07-31

本研究对6例初治和6例TACE后HCC样本行单核RNA测序,发现TACE后残留肿瘤血管高血管生成且不成熟并伴免疫抑制,PDGFC+ TAM促进血管周细胞向CAF转化。临床前模型显示低剂量抗VEGF-A联合抗PD-L1可改善缺氧、减少PDGFC+ TAM、增强CD8+ T细胞免疫并改善肿瘤控制,回顾性分析支持低剂量贝伐珠单抗联合阿替利珠单抗改善TACE后结局并保留肝功能。

要点

  • TACE后残留HCC血管高血管生成、结构不成熟并伴免疫抑制。
  • PDGFC+ TAM驱动血管周细胞向CAF转化,强化血管生成与免疫抑制正反馈。
  • 低剂量贝伐珠单抗联合阿替利珠单抗或可改善TACE后结局并保留肝功能。

核心结论

  • TACE诱导PDGFC+ TAM介导的血管免疫微环境功能障碍。
  • 低剂量贝伐珠单抗联合阿替利珠单抗可能通过促进血管正常化和增强抗肿瘤免疫 counteracting 该病理微环境。

研究设计与样本

  • 对6例初治和6例TACE后HCC肿瘤样本行单核RNA测序。
  • 通过多重免疫组化、血浆生物标志物、公共转录组数据集和回顾性临床分析在5个独立队列中验证。
  • 使用多种体内HCC模型研究PDGFC-PDGFR轴并评估低剂量抗VEGF-A联合抗PD-L1治疗。

主要发现

  • TACE后残留肿瘤血管血管生成活性增高但结构不成熟,并伴免疫抑制特征。
  • TACE使TAM和CAF重编程为促血管生成和免疫抑制状态。
  • PDGFC+ TAM作用于周细胞和CAF,诱导周细胞向CAF转化并激活基质重塑程序。
  • 临床前HCC模型中,低剂量抗VEGF-A联合抗PD-L1减轻缺氧、减少PDGFC+ TAM积累、增强CD8+ T细胞免疫并改善肿瘤控制。
  • 回顾性临床分析支持低剂量贝伐珠单抗联合阿替利珠单抗改善TACE后临床结局并保留肝功能。

临床怎么用

  • 为HCC患者TACE后评估剂量优化抗血管生成治疗联合免疫检查点阻断提供转化依据。
  • 低剂量贝伐珠单抗联合阿替利珠单抗可能作为TACE后改善微环境并保留肝功能的策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) commonly results in residual disease; however, the angiogenic features of residual tumors remain poorly defined. This study aimed to characterize vascular niche remodeling after TACE and provide a translational rationale for optimizing combination therapy. METHODS: We performed single-nucleus RNA sequencing on six treatment-naive and six post-TACE HCC tumor samples. The findings were subsequently validated across five independent cohorts using multiplex immunohistochemistry, plasma biomarker assays, public transcriptomic datasets, and retrospective clinical analyses. Multiple in vivo HCC models were further used to investigate the PDGFC-PDGFR axis and evaluate low-dose anti-VEGF-A plus anti-PD-L1 therapy. RESULTS: Residual tumor vessels following TACE exhibited heightened angiogenic activity while remaining structurally immature, with accompanying immunosuppressive features. Integrated analyses revealed that TACE markedly reprogrammed tumor-associated macrophages (TAMs) and cancer-associated fibroblasts (CAFs) toward pro-angiogenic and immunosuppressive states. Notably, PDGFC+ TAMs acted on pericytes and CAFs to induce pericyte-to-CAF transition and activate stromal remodeling programs, thereby reinforcing a positive feedback loop linking aberrant angiogenesis and immunosuppression. More importantly, in preclinical HCC models, low-dose anti-VEGF-A plus anti-PD-L1 alleviated hypoxia, reduced PDGFC+ TAM accumulation, enhanced CD8+ T-cell immunity, and improved tumor control. Retrospective clinical analysis further supported the potential of low-dose bevacizumab plus atezolizumab to improve clinical outcomes while preserving hepatic function after TACE. CONCLUSIONS: This study demonstrates that TACE induces PDGFC+ TAM-mediated dysfunction of the vascular-immune microenvironment. Low-dose bevacizumab plus atezolizumab may counteract this pathological microenvironment by promoting vascular normalization and enhancing antitumor immunity, thereby representing a promising therapeutic strategy. IMPACT AND IMPLICATIONS: Transarterial chemoembolization (TACE) commonly leaves residual tumors in hepatocellular carcinoma (HCC); however, tumor angiogenic features in this context remain poorly defined. By integrating single-nucleus transcriptomics with multi-cohort validation, this study shows that residual tumors exhibit a hypoxic, angiogenic, and structurally immature vascular niche accompanied by immunosuppression. PDGFC+ tumor-associated macrophages emerged as a central component of this niche and may promote pericyte-to-fibroblast transition, cancer-associated fibroblast activation, and pathological angiogenesis. In preclinical HCC models, low-dose anti-VEGF-A plus anti-PD-L1 therapy alleviated hypoxia, reduced PDGFC+ macrophage accumulation, increased pericyte coverage, enhanced CD8+ T-cell immunity, and improved tumor control. Retrospective clinical analysis further suggested that low-dose bevacizumab plus atezolizumab may improve clinical outcomes while preserving hepatic function after TACE. These findings provide a translational rationale for further evaluating dose-optimized anti-angiogenic therapy plus immune checkpoint blockade in patients with HCC undergoing TACE.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Zhao C, Yan H, Liang Z, et al. Low-dose bevacizumab plus atezolizumab enhances transarterial chemoembolization in HCC via correcting vascular-immune niche dysfunction. J Hepatol. 2026. PMID: 42537705. doi:10.1016/j.jhep.2026.07.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。